Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Clinical Trials as Topic
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology*
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy
  • Lambert-Eaton Myasthenic Syndrome / complications
  • Lambert-Eaton Myasthenic Syndrome / drug therapy
  • Lambert-Eaton Myasthenic Syndrome / therapy*
  • Myasthenia Gravis / complications*
  • Myasthenia Gravis / drug therapy
  • Myasthenia Gravis / therapy*
  • Pandemics*
  • Plasma Exchange
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / epidemiology*
  • SARS-CoV-2
  • Vaccines

Substances

  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Immunosuppressive Agents
  • Vaccines

Supplementary concepts

  • COVID-19 drug treatment